Alzheimer's drug rejected by EMA
The Alzheimer's drug lecanemab has not been approved by the European Medicines Agency EMA. The benefits are not considered to outweigh the potential drawbacks. A review of the decision will be requested, announces Swedish Bioarctic – whose share plummeted on the news.
Sweden